Immunogenicity of Mepolizumab in Patients with Severe Eosinophilic Asthma: Experience from the Clinical Development Program

Ortega, Héctor; Meyer, Erik; Asano, Koichiro; Price, Robert G.; Prazma, Charlene M.; Albers, Frank C.; Yancey, Steven W.; Gleich, Gerald J.

doi:10.1183/13993003.congress-2018.oa1650

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The decline in the percentage of patients using mOCS over time is not due to cessation of mepolizumab by mOCS users, as the percentage of patients who used mOCS is smaller in the group of patients that discontinued mepolizumab compared to patients that continued mepolizumab. Neutralizing anti-drug antibodies are probably rare (21). The decrease in response rate 6 months from the initiation of mepolizumab could be due to patients who show a partial response that is not convincing at first, and in which the period of evaluation is therefore extended.…”

Section: Discussionmentioning

confidence: 99%

Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety

et al. 2020

View full text Add to dashboard Cite

Introduction: Severe eosinophilic asthma is an incapacitating disease. Mepolizumab, a humanized anti-interleukin-5 monoclonal antibody, proved to be effective as an add-on therapy in patients with severe eosinophilic asthma. However, only data from randomized controlled trials are available and real world data are lacking. Methods: A retrospective observational longitudinal study was conducted in a real world cohort of patients with severe eosinophilic asthma treated with mepolizumab. The primary objective was to determine response rate, based on a global evaluation of treatment effectiveness by the treating pulmonologist. Secondary objectives were to assess exacerbation frequency, systemic maintenance glucocorticoid usage, Asthma Control Questionnaire (ACQ), lung function, and adverse events. Results: Seventy-eight patients were included. Treatment with mepolizumab was considered beneficial and was therefore continued in 75.6% of patients 12 months from the initiation of mepolizumab. The most common reason for drop-out was insufficient response. Secondary objectives: 12 months from the initiation of mepolizumab there was a decrease of 3.2 (CI 2.5-4.1; p < 0.001) severe asthma exacerbations per year, a decrease of ACQ of 0.80 points (CI 0.49-1.12; p < 0.001), and an increase of 3.7 (CI 0.3-7.2; p ¼ 0.034) percent of predicted FEV1 compared to baseline. At baseline 51.3% of patients were treated with systemic glucocorticoid maintenance therapy, compared to 15.4% (p < 0.001) of patients 12 months from the initiation of mepolizumab. No serious adverse events considered to be related to mepolizumab were reported. Conclusion:This study confirms that mepolizumab add-on therapy is effective and safe in a real world cohort of patients with severe eosinophilic asthma.

show abstract

Section: Discussionmentioning

confidence: 99%

Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety

et al. 2020

View full text Add to dashboard Cite

show abstract

“…O rtega et al. [ 26 ] have looked at the immunogenicity profile of mepolizumab during the Phase III clinical development programme in severe asthma (COSMOS and COLUMBA). There was no correlation between anti-drug antibody titres and change in BECs.…”

Section: Asthmamentioning

confidence: 99%

Research highlights from the 2018 European Respiratory Society International Congress: airway disease

et al. 2019

View full text Add to dashboard Cite

The annual European Respiratory Society (ERS) International Congress (held in Paris in 2018) was once again a platform for discussion of the highest-quality scientific research, cutting-edge techniques and innovative new therapies within the respiratory field. This article discusses only some of the high-quality research studies presented at this year's Congress, with a particular focus on airway diseases including asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis and cough, as presented through Assembly 5 of the ERS (Airway Diseases: Asthma and COPD). The authors establish the key take-home messages of these studies, compare their findings and place them in the context of current understanding.

show abstract

Immunogenicity of Mepolizumab in Patients with Severe Eosinophilic Asthma: Experience from the Clinical Development Program

Cited by 2 publications

References 0 publications

Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety

Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety

Research highlights from the 2018 European Respiratory Society International Congress: airway disease

Contact Info

Product

Resources

About